The convergence of big data, cloud computing, and artificial intelligence has allowed twoXAR to build a drug discovery platform that is order of magnitudes faster, cheaper, and more accurate than traditional wet-lab based approaches.

twoXAR leverages its technology internally to build its own pipeline of therapeutic candidates across diseases as well as collaborate with biotechnology and pharmaceutical companies to jointly discover and develop novel drug candidates by:

- Screening compound libraries for efficacy against a disease or list of diseases
- Screening compound libraries for efficacy against a disease or list of diseases
- Identifying biologic targets from the elucidation of novel biology